



BioPharmica Limited

Successful HLS5 Cancer Gene Pre-clinical Trial

- Results received from pre-clinical trial
- Majority of specific cancer types had an HLS5 gene fault
- Direct correlation of a faulty HLS5 gene and cancer in humans

ASX Announcement – 16 May 2005

BioPharmica (ASX: BPH) is pleased to announce successful results of work conducted by the Western Australian Institute for Medical Research (WAIMR) on the HLS5 cancer gene.

A pre-clinical trial was conducted at the Royal Perth Hospital campus of WAIMR involving a 70-sample study of the HLS5 cancer marker in normal and confirmed cancers (breast, prostate, lung and colon), as well as a panel of cancer cell lines.

- **The pre-clinical trial was an outstanding success with WAIMR scientists directly correlating the presence of a fault in the HLS5 gene and the development of cancer in humans.**
- **Results showed that over 50% of patients with particular types of cancer had a fault in their HLS5 gene.**
- **Scientists were also able to determine the specific types of cancer in which the HLS5 gene fault occurs.**
- **A very sensitive test for detecting the HLS5 cancer gene marker was developed and used in the pre clinical trial.**

The company is extremely pleased with the outcome of the pre-clinical trial. All goals and objectives were achieved and significant additional intellectual property has been developed as a result of the work being conducted by WAIMR and BioPharmica.

Genetic testing for cancer with diagnostic tests using genes such as HLS5 are extremely promising as they may lead to cancer being found at an earlier, more treatable stage.

Media Inquiries: Mr. David Breeze 08 9244 9361

About BioPharmica

BioPharmica is working to commercialise a portfolio of Australian biomedical research discovered by Australian universities, medical institutes and hospitals targeting large global markets. The Company has several projects currently undergoing pre-clinical development in Australian Hospitals and Universities.

In conjunction with the University of Western Australia and the Western Australian Institute for Medical Research, the Company is working to commercialise a molecular marker for early and accurate cancer detection. The HLS5 genetic marker is currently undergoing pre-clinical work at the Royal Perth Hospital campus of WAIMR.



BioPharmica Limited

In partnership with Cortical Dynamics Pty Ltd, the Company is working to commercialise the BAR Monitor, a device that measures a patient's brain electrical activity (EEG) to indicate the response to drugs administered during surgery. The BAR Monitor assists doctors to ensure patients do not wake up unexpectedly during an operation, and minimizes associated side effects from post-operative recall of surgical procedures. The BAR Monitor is currently undergoing validation trials with data from patients at Royal Melbourne Hospital.

Together with the Royal Melbourne Institute of Technology University and Diagnostic Array Systems, the Company is working to commercialise faster and more effective methods of detecting infectious diseases using the genetic structure (DNA) of bacteria. Founders Dr Benjamin Fry and Dr Viraj Nawagamuwa are both world leaders in the genetic structure of bacteria.

In conjunction with Swinburne University of Technology and Dr Paul Stoddart, BioPharmica is working to commercialise the SERS Probe, a fibre optic probe to be used in biosensors for diagnostic testing and drug development. The probe enables the microscopic tip of an optical fibre to be used in biosensors to detect and monitor biological and chemical targets.